

EXPRESS MAIL: EL421 020US  
DATE: 1 November 2000



P50464-1X1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Jackson et al.  
Serial No.: 09/142,983  
Filing Date: 17 September 1998  
For: PLA<sub>2</sub> Inhibitors for Angiogenesis

1 November 2000  
Group Art Unit No. 1614  
Examiner: T. Criares

RECEIVED

Assistant Commissioner of Patents  
Washington, D.C. 20231

NOV 03 2000

RESPONSE

TECH CENTER 1600/2900

Sir:

In response to the Examiner's office action of 4 May 2000 in the above noted application, please enter the following remarks and amendments into the record. Enclosed herewith is a continuation prosecution application transmittal letter and the petition for a three (3) month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account. Entry of this amendment therein is requested.

**In the Claims:**

Please add the following claims:

14. A method of treating a chronic disease in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis, with an effective amount of a compound which inhibits the production, transcription, translation or activity of 14 kDa PLA<sub>2</sub> and wherein the compound was used before or invented after the priority date of March 26, 1996.

15. A method of treating a chronic disease of diabetic retinopathy or ocular neovascularization in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis with an effective amount of a compound which inhibits the production, transcription, translation or activity of 14 kDa PLA<sub>2</sub> and wherein the compound was used before or invented after the priority date of March 26, 1996.

16. A method of treating a chronic disease of tumor growth and metastasis in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis with an effective amount of a compound which inhibits the production, transcription, translation or activity of 14 kDa PLA<sub>2</sub> and wherein the compound was used before or invented after the priority date of March 26, 1996.